Cite

HARVARD Citation

    Bures, J. et al. (2017). Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite. Toxicology. pp. 1-10. [Online]. 
  
Back to record